Samuel R. Nussbaum M.D. is EVP & Chief Medical Officer at WELLPOINT, INC (WLP). They have made 11 open-market trades across 2 companies since 2007, most recently 2021-06-14.
CIK 0001199310
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $50K since 2018, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MOTS | BUY | 2018-02-16 | 2018-02-21 | $5.00 | $50K | +14.4% | +9.1% | +11.6% |
| ANTM | SELL · 10b5-1 | 2015-05-19 | 2015-05-21 | $165.00 | $1.6M | -2.8% | +0.9% | +0.9% |
| ANTM | SELL · 10b5-1 | 2015-05-11 | 2015-05-13 | $160.00 | $1.6M | -2.8% | +0.9% | +0.9% |
| ANTM | SELL · 10b5-1 | 2015-04-13 | 2015-04-15 | $154.83 | $7.6M | -2.8% | +0.9% | +0.9% |
| WLP | SELL · 10b5-1 | 2014-10-31 | 2014-11-04 | $125.00 | $5.0M | N/A | N/A | N/A |
| WLP | SELL | 2014-09-11 | 2014-09-15 | $120.00 | $2.4M | N/A | N/A | N/A |
| WLP | SELL | 2014-08-27 | 2014-08-29 | $116.05 | $4.6M | N/A | N/A | N/A |
| WLP | SELL | 2013-09-13 | 2013-09-17 | $89.20 | $10.5M | N/A | N/A | N/A |
| WLP | SELL | 2013-09-11 | 2013-09-13 | $89.29 | $3.8M | N/A | N/A | N/A |
| WLP | SELL · 10b5-1 | 2013-05-07 | 2013-05-08 | $75.00 | $1.9M | N/A | N/A | N/A |
| WLP | SELL | 2011-06-14 | 2011-06-15 | $78.01 | $1.1M | N/A | N/A | N/A |
| WLP | SELL | 2011-04-29 | 2011-05-03 | $76.48 | $5.4M | N/A | N/A | N/A |
| WLP | SELL | 2007-12-14 | 2007-12-18 | $86.14 | $2.2M | N/A | N/A | N/A |
| WLP | SELL | 2007-11-28 | 2007-11-29 | $84.00 | $840K | N/A | N/A | N/A |
| WLP | SELL | 2007-02-07 | 2007-02-09 | $80.90 | $809K | N/A | N/A | N/A |
| WLP | SELL | 2007-02-01 | 2007-02-05 | $79.35 | $794K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.